Knight Therapeutics | GUD - Loan Capital


Knight Therapeutics reported CAD57.78M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Acasti Pharma USD 0 0 Dec/2024
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Aurora Cannabis CAD 18.13M 15.07M Mar/2026
Avita Medical AUD 42.24M 1.25M Dec/2024
Canopy Growth CAD 217.12M 7.87M Mar/2026
Dianthus Therapeutics USD 0 0 Dec/2024
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
IQVIA Holdings USD 13.99B 105M Mar/2026
Knight Therapeutics CAD 57.78M 26.92M Dec/2025
Moderna USD 603M 7M Mar/2026
Omeros USD 403.72M 27.2M Jun/2024
Organigram Holdings CAD 60.76M 1.77M Mar/2026
Organon & Co USD 8.55B 75M Mar/2026
Revvity USD 2.63B 836K Mar/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
Tilray USD 268.59M 3.82M Sep/2025
Viatris USD 12.41B 67.1M Mar/2026
Xeris Pharmaceuticals USD 221.22M 889K Mar/2026